

Trials

GoPerio - Impact of a personalized video and an automated two-way text-messaging system in oral hygiene motivation: study protocol for a randomized controlled trial --Manuscript Draft--

Manuscript Number:	TRLS-D-18-00981R1	
Full Title:	GoPerio - Impact of a personalized video and an automated two-way text-messaging system in oral hygiene motivation: study protocol for a randomized controlled trial	
Article Type:	Study protocol	
Funding Information:	Association for Dental Education in Europe (IE) (Scholarship for the advancement of video dentistry in dental education)	Dr. Valentin Garyga
Abstract:	<p>Background Oral hygiene is of paramount importance for the preservation of oral health, and for patients affected by periodontal disease establishing an effective oral hygiene routine is the first step of therapy. Several clinical frameworks have been developed to foster behavior change, such as motivation interviewing. However, two obstacles can be identified. First, patients tend to forget the advice they were given during the consultation. Second, it is hard to maintain motivation in the long-term, thus leading to relapse. An innovative eHealth solution was designed with the aim to tackle both obstacles and supplement the current clinical standard of care. The primary objective is to compare at 8 weeks of follow-up the full mouth plaque scores of study groups (eHealth plus standard of care vs. standard of care only). The main secondary objective is to compare at 8 weeks of follow-up the full mouth bleeding score.</p> <p>Methods/Design The "GoPerio" study is a multicenter, randomized, controlled trial assessing the impact of a novel eHealth concept for oral hygiene motivation (personalized video of oral hygiene routine available for the patient via a cloud server plus interactive text messages) in addition to the current standard of care (motivational interviewing plus tooth scaling and polishing). The minimum sample size required is 86 patients. Randomization will be performed (allocation ratio 1:1): test group (eHealth plus standard of care) vs. control group (standard of care only). The primary outcome is oral hygiene as measured by the full mouth (6 sites per tooth) plaque control record (PCR) index. The main secondary outcome is gingival inflammation as measured by the full mouth (6 sites per tooth) bleeding on probing (BOP) index. Both the primary and the main secondary outcomes are evaluated at 8 weeks of follow-up by blinded and calibrated examiners. The other secondary outcomes are patient satisfaction and patient behavior change and motivation. Discussion The study will investigate the value of an innovative eHealth approach to strengthen patient motivation for oral hygiene. If proven effective, such an approach would supplement the current clinical standard of care, resulting in improved clinical outcomes with negligible impact on productivity of a dental practice. Trial registration ClinicalTrials.gov Identifier NCT03109808 (registered in April 2017) Sponsor Hospices Civils de Lyon. BP 2251, 3 quai des Célestins, 69229 Lyon cedex 02. Protocol version 1.0 as of September 21, 2016.</p>	
Corresponding Author:	Valentin Garyga, DDS Hospices Civils de Lyon Lyon, Auvergne Rhône-Alpes FRANCE	
Corresponding Author E-Mail:	valentin@valentingaryga.com;valentin.garyga@chu-lyon.fr	
Corresponding Author Secondary Information:		
Corresponding Author's Institution:	Hospices Civils de Lyon	
Corresponding Author's Secondary Institution:		
First Author:	Valentin Garyga	
First Author Secondary Information:		

Order of Authors:	Valentin Garyga Florian Pochelu Béatrice Thivichon-Prince Walid Aouini Julie Santamaria France Lambert Delphine Maucort-Boulch François Gueyffier Kerstin Gritsch Brigitte Grosgeat
Order of Authors Secondary Information:	
Response to Reviewers:	<p>Dear colleagues,</p> <p>We would like to thank both reviewers for their work and for the relevant criticism they raised.</p> <p>The questions of reviewer 1 regarding the content of format of the text messages reminders highlighted the need for clarification in the manuscript. As such, a paragraph dedicated to the text message reminders was added to the manuscript from line 299 to line 320. We hope this brings the much needed information regarding the system we investigate.</p> <p>We also addressed reviewer 2's question regarding the technical platform for the video and whether they are available through a specific app or if a particular operating system is needed by adding the requested information to the manuscript (line 288 to line 292).</p> <p>Reviewer 2's concern regarding the inclusion criteria, especially the age of participants are relevant. When it comes to adoption of technology, age can be a very relevant factor. Aged patients may experience more difficulties. To encourage adoption in the elderly, we streamlined the user experience as much as possible, notably through the use of a web portal, rather than a dedicated application to view videos ; and the text reminders sent to patients contain a direct link to their video. This much needed clarification has been added to the manuscript in the Discussion section (lines 463 to 474)</p> <p>Reviewer 2 raised a valid point concerning the evaluation period. The 8-weeks follow-up considered in our protocol aims to evaluate the added value of our eHealth solution for the acquisition of a satisfactory oral hygiene routine, notably preliminary to initial periodontal therapy. This evaluation period is too short to allow the exploration of the long-term maintenance of this oral hygiene routine, a much needed element when considering maintenance of periodontally compromised patients after treatment of periodontitis. To address reviewer's concerns, we further clarified these elements in the discussion through additions lines 521 to 524 and lines 528 to 533.</p> <p>The rationale for choosing electric toothbrushes require further clarification, as highlighted by reviewer 2's comment. Our study focuses on the comparison between video + SMS and no video + no SMS so choosing one model of toothbrush for all patients was preferred, in order to reduce bias linked to the tool. Electric toothbrush were considered over manual toothbrushes as they have proven to be more efficient for plaque removal, and one can consider electric toothbrushes to be less technique sensitive than manual toothbrushes. We have brought more details to the manuscript and emphasized the need for further studies in that area. Revisions are appear lines 506 and 509-517.</p> <p>To answer reviewer 2's concern regarding the sample size, the sample size was calculated by biostatisticians who co-authored the manuscript. The relevant paragraph is located lines 190-198. We remain available to answer any additional question and</p>

provide all details between the sample size calculation and its underlying hypotheses if deemed relevant.

We are thankful to reviewer 2 for spotting a mistake in the inclusion periods. We corrected that to take into account the actual start date of the recruitment (March 2017) and the projected end date for the end of inclusions (December 2019). Inclusion period had to be extended to meet the sample size. Corrections appear in the manuscript line 156.

The question from reviewer 2 regarding other oral conditions that might be diagnosed during the course of the trial led us to provide further clarification. Modifications were made to the manuscript lines 226 and 228-232. We hope this addresses reviewer 2's concerns.

Reviewer 2 raised points concerning the use of adjunctive chemical plaque control agents. Unfortunately, most guidelines available in the literature give a lot of lee-way for clinicians to adapt to the individual clinical situation (Tonetti MS, Eickholz P, Loos BG, Papapanou P, van der Velden U, Armitage G, et al. Principles in prevention of periodontal diseases. J Clin Periodontol. 2015;42:S5–11. doi:10.1111/jcpe.12368.). This situation is problematic for clinical trials as it may induce biases. We tried to clarify the way we would use antimicrobial agents in the course of the trial and also acknowledge the fact that the use of chemical agents should be recorded in the eCRF. Additions were made to the manuscript lines 242-245.

A very important point regarding continuity of routine and care was raised by reviewer 2 when discussing if patients will have the financial conditions to follow the protocol taught to them. We have clarified that patients will be able to keep all the materials that were given to them during the study and that refills or replacement products are easily available in the market. Modifications to the manuscript appear lines 253-257.

Regarding a possible follow-up visit a 1 year, reviewer 2 rightfully recommended for such visit to be conducted by researchers to standardize protocol. Unfortunately, due to French law, we cannot prevent the patient from requesting a follow-up visit at 1 year with an other care provider. If patient would choose another care provider for the 1 year check-up, they would automatically qualify as lost to follow-up for our study. However, should they accept to have a 1 year follow-up visit within the framework of our study, this examination would be conducted by the researchers with the same protocol. We tried to balance the ethical and legal aspects with the research and methodological considerations as best as we could. Further clarification was brought to the manuscript lines 357-359 and lines 531-533.

Reviewer 2 highlighted the need to include the the Dental Visit Satisfaction Scale (DVSS) in supplementary material. We included the DVSS in the Supplementary File 1 and acknowledge that this inclusion will help readers to go in more details of our study. For the sake of harmonization, we have also added the behavioral questionnaire used in visit 3 in Supplementary File 2.

Reviewer 2 requested further information regarding warnings / notifications about videos in the smartphones. This relevant information was clarified in the manuscript lines 291-292.

Finally, we would like to thank both reviewers for the extensive work. We believe their comments and criticisms have helped improve the manuscript, both regarding the methodology and the clarity. We hope our answer fulfill their expectations and brought all necessary details. We remain available for further exchange and improvements.

Best regards,

Valentin GARYGA et al.

Additional Information:	
Question	Response
Covering letter concerning your	Dear Editor,

manuscript	<p>We wish to submit a new manuscript entitled “GoPerio - Impact of a personalized video and an automated two-way text-messaging system in oral hygiene motivation: study protocol for a randomized controlled trial” for consideration by Trials.</p> <p>We confirm that this work is original and has not been published nor is currently under consideration for publication elsewhere.</p> <p>In this paper, we present the protocol for a multicenter randomized controlled trial evaluating an innovative approach for oral hygiene motivation. This trial is currently ongoing in France and Belgium.</p> <p>During the consultation, the dentist records a personalized video for each patient thanks to a miniature camera mounted on the dental loupes. This video depicts all procedures for oral hygiene and is tailored to the patient’s needs, tools, and skills. The video is sent to the patient on his smartphone or tablet via a cloud system. Additionally, personalized motivational text messages are automatically sent to the patient to increase adherence to their new oral hygiene routine.</p> <p>The novelty of our concept resides in the use of personalized videos, coming on top of a motivational interview with the patient. This solution is unique for each patient and as we make it available for them on their smartphones or tablets they can access reliable information anywhere, anytime. The use of text messages has proved beneficial to increase adherence to therapy in other chronic diseases. We wanted to investigate this technology for oral health too.</p> <p>We would like to share this protocol with the scientific community to be fully transparent and hopefully benefit from our peers’ opinions to further improve our work.</p> <p>As specified in the authors instructions we would like to propose the following potential reviewers:</p> <p>-Dr. Olivier HUCK, Université de Strasbourg, Strasbourg, France (huck.olivier@gmail.com - https://bit.ly/2CSF611)</p> <p>-Dr. Marjolaine GOSSET, Université Paris Descartes, Paris, France (marjolaine.gosset@parisdescartes.fr - https://bit.ly/2SvqzgY)</p> <p>As for competing interests, we declare that no authors or investigators received funding from industrial partners. However, both centers involved in the present research protocol received free-of-charge materials (electric toothbrushes, toothpastes, interdental brushes, dental floss, professional prophylaxis materials) and devices (video cameras). The industrial partners providing materials are listed in the manuscript. Nevertheless, the industrial partners did not have any involvement in the study design or in the analysis, collection and interpretation of the data, or in drafting of the manuscript. No other relationships or activities could appear to have influenced the submitted work.</p> <p>We confirm that all authors have approved the manuscript for submission and authorship complies by ICJME standards.</p> <p>Thank you for your consideration of this manuscript.</p> <p>Sincerely, Valentin Garyga</p>
<p>Is this study a clinical trial? A clinical trial is defined by the World Health Organisation as ‘any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes’.</p>	Yes
<p>We require registration of all clinical trials that are reported in manuscripts submitted to the journal. More information about trial registration, including the trial</p>	NCT03109808

<p>registries that currently meet all of the ICMJE guidelines, can be found in the FAQ section of "About ICMJE" at <a _blank"="" href="http://www.icmje.org/about-icmje/faqs/clinical-trials-registration/">http://www.icmje.org/about-icmje/faqs/clinical-trials-registration/. Please provide the following information where prompted: Enter the Trial Registration Number: as follow-up to "Is this study a clinical trial?" A clinical trial is defined by the World Health Organisation as 'any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes'.</p>	
<p>Enter the name of the registry: as follow-up to "Is this study a clinical trial?" A clinical trial is defined by the World Health Organisation as 'any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes'.</p>	<p>clinicaltrials.gov</p>
<p>Enter the URL of the trial registry record: as follow-up to "Is this study a clinical trial?" A clinical trial is defined by the World Health Organisation as 'any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes'.</p>	<p>https://clinicaltrials.gov/ct2/show/NCT03109808?term=goperio&rank=1</p>
<p>Enter the date that you registered your trial (in mm/dd/yyyy format): as follow-up to "Is this study a clinical trial?" A clinical trial is defined by the World Health Organisation as 'any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes'.</p>	<p>04-12-2017</p>
<p>Enter the date of enrolment of the first participant to the trial (in mm/dd/yyyy format): as follow-up to "Is this study a clinical trial?" A clinical trial is defined by the World Health Organisation as 'any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes'.</p>	<p>04-12-2017</p>
<p>Was your trial registered before the first participant was enrolled? (i.e.</p>	<p>Yes</p>

<p>prospectively registered)
&nbsp;as follow-up to "Is this study a clinical trial?<hr><i>A clinical trial is defined by the World Health Organisation as 'any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes'.</i>"</p>	
<p>Within your manuscript, have you also included details of your trial registration at the end of your abstract?</p> <ul style="list-style-type: none"> Name of the registry trial date="" url="" li>="" li><="" number<="" of="" record<="" registration="" registration<="" registry="" trial="" ul=""> <p>

 <i>Example: Trial registration: ISRCTN, ISRCTN12345678. Registered 28 September 2014, http://www.isrctn.com/ISRCTN12345678</i>
&nbsp;as follow-up to "Was your trial registered before the first participant was enrolled? (i.e. prospectively registered) "</p> trial>	<p>I confirm I have provided trial registration details at the end of the abstract</p>
<p>Does your study have ethical approval?</p>	<p>Yes, and I have included the relevant documentation as an additional file</p>
<p>Has your study received funding?</p>	<p>Yes, the funding is internal or industry funded, and I have included the relevant documentation as an additional file</p>
<p>Is your study protocol reported in accordance with the SPIRIT Guidelines?</p>	<p>Yes, and I have included a populated SPIRIT checklist as an additional file and the SPIRIT figure is included in the main body of the manuscript</p>
<p>What stage of participant recruitment is your study at?</p>	<p>Participant recruitment is in progress</p>

[Click here to view linked References](#)

1 **GoPerio - Impact of a personalized video and an automated two-way text-messaging**
2 **system in oral hygiene motivation: study protocol for a randomized controlled trial**

3
4
5 3
6
7 4 Valentin Garyga, Florian Pochelu, Béatrice Thivichon-Prince, Walid Aouini, Julie Santamaria,
8
9 5 France Lambert, Delphine Maucort-Boulch, François Gueyffier, Kerstin Gritsch, Brigitte
10
11 6 Grosogoeat

12
13
14 7
15
16 8 **Corresponding author:** Brigitte Grosogoeat. UFR d'Odontologie. 11 rue Guillaume Paradin.
17
18 9 69372 Lyon Cedex 08. France. brigitte.grosogoeat@univ-lyon1.fr

19
20
21 10
22
23 11 Valentin Garyga. *Université de Lyon, Université Lyon 1, Faculté d'odontologie, Lyon, France*
24
25 12 ; *Hospices Civils de Lyon, Service de Consultations et Traitements Dentaires, Lyon, France*
26
27 13 . valentin.garyga@chu-lyon.fr

28
29 14 Florian Pochelu. *Hospices Civils de Lyon, Service de Consultations et Traitements Dentaires,*
30
31 15 *Lyon, France.* pochelu.florian@gmail.com

32
33 16 Béatrice Thivichon-Prince. *Université de Lyon, Université Lyon 1, Faculté d'odontologie,*
34
35 17 *Lyon, France ; Hospices Civils de Lyon, Service de Consultations et Traitements Dentaires,*
36
37 18 *Lyon, France ; Université de Lyon, IGFL UMR 5242, Lyon, France.* [beatrice.thivichon-](mailto:beatrice.thivichon-prince@univ-lyon1.fr)
38
39 19 [prince@univ-lyon1.fr](mailto:beatrice.thivichon-prince@univ-lyon1.fr)

40
41 20 Walid Aouini. *Université de Monastir, Monastir, Tunisia ; CHU de Liège, Liège, Belgium.*
42
43 21 aouiniwalid131177@gmail.com

44
45 22 Julie Santamaria. *Hospices Civils de Lyon, Service de Consultations et de Traitements*
46
47 23 *Dentaires, Lyon, France.* julie.santamaria@chu-lyon.fr

48
49 24 France Lambert. *Université de Liège, Liège, Belgium ; CHU de Liège, Liège, Belgium ; Dental*
50
51 25 *Biomaterials Research Unit, Liège, Belgium.* france.lambert@chu.ulg.ac.be

26 Delphine Maucort-Boulch. *Université de Lyon, Université Lyon 1, Lyon, France ; Hospices*
27 *Civils de Lyon, Service de Biostatistique-Bioinformatique, Lyon, France ; Université de Lyon,*
28 *CNRS UMR 5558, Laboratoire de Biométrie et Biologie Évolutive, Département Biostatistiques*
29 *et Modélisation pour la Santé et l'environnement, Villeurbanne, France [delphine.maucort-
boulch@chu-lyon.fr](mailto:delphine.maucort-
boulch@chu-lyon.fr)*

31 Francois Gueyffier. *Université de Lyon, Université Lyon 1, Lyon, France ; Hospices Civils de*
32 *Lyon, Hôpital Cardiologique, Bron, France ; Université de Lyon, CNRS UMR 5558,*
33 *Laboratoire de Biométrie et Biologie Évolutive, Département Biostatistiques et Modélisation*
34 *pour la Santé et l'environnement, Villeurbanne, France. francois.gueyffier@univ-lyon1.fr*

35 Kerstin Gritsch. *Université de Lyon, Université Lyon 1, Faculté d'odontologie, Lyon, France ;*
36 *Hospices Civils de Lyon, Service de Consultations et de Traitements Dentaires, Lyon, France ;*
37 *Université de Lyon, LMI UMR CNRS 5615, Lyon, France. kerstin.gritsch@univ-lyon1.fr*

38 Brigitte Grosogeat. *Université de Lyon, Université Lyon 1, Faculté d'odontologie, Lyon,*
39 *France ; Hospices Civils de Lyon, Service de Consultations et de Traitements Dentaires, Lyon,*
40 *France, Lyon, France ; Université de Lyon, LMI UMR CNRS 5615, Lyon, France.*
41 *brigitte.grosogeat@univ-lyon1.fr*

43 **ABSTRACT**

44 **Background:** Oral hygiene is of paramount importance for the preservation of oral health, and
45 for patients affected by periodontal disease establishing an effective oral hygiene routine is the
46 first step of therapy. Several clinical frameworks have been developed to foster behavior
47 change, such as motivation interviewing. However, two obstacles can be identified. First,
48 patients tend to forget the advice they were given during the consultation. Second, it is hard to
49 maintain motivation in the long-term, thus leading to relapse. An innovative eHealth solution
50 was designed with the aim to tackle both obstacles and supplement the current clinical standard

1 of care. The primary objective is to compare at 8 weeks of follow-up the full mouth plaque
2 scores of study groups (eHealth plus standard of care vs. standard of care only). The main
3
4 secondary objective is to compare at 8 weeks of follow-up the full mouth bleeding score.
5

6
7 **Methods/Design:** The “GoPerio” study is a multicenter, randomized, controlled trial assessing
8
9 the impact of a novel eHealth concept for oral hygiene motivation (personalized video of oral
10 hygiene routine available for the patient via a cloud server plus interactive text messages) in
11
12 addition to the current standard of care (motivational interviewing plus tooth scaling and
13
14 polishing). The minimum sample size required is 86 patients. Randomization will be performed
15
16 (allocation ratio 1:1): test group (eHealth plus standard of care) vs. control group (standard of
17
18 care only). The primary outcome is oral hygiene as measured by the full mouth (6 sites per
19
20 tooth) plaque control record (PCR) index. The main secondary outcome is gingival
21
22 inflammation as measured by the full mouth (6 sites per tooth) bleeding on probing (BOP)
23
24 index. Both the primary and the main secondary outcomes are evaluated at 8 weeks of follow-
25
26 up by blinded and calibrated examiners. The other secondary outcomes are patient satisfaction
27
28 and patient behavior change and motivation.
29
30
31
32
33
34
35

36 **Discussion:** The study will investigate the value of an innovative eHealth approach to
37
38 strengthen patient motivation for oral hygiene. If proven effective, such an approach would
39
40 supplement the current clinical standard of care, resulting in improved clinical outcomes with
41
42 negligible impact on productivity of a dental practice.
43
44
45

46 **Trial registration:** ClinicalTrials.gov Identifier NCT03109808 (registered in April 2017)
47

48 **Sponsor:** Hospices Civils de Lyon. BP 2251, 3 quai des Célestins, 69229 Lyon cedex 02.
49

50
51 **Protocol version:** 1.0 as of September 21, 2016.
52

53 **Keywords:** Oral hygiene; Motivational Interviewing; Patient Education as Topic; Patient
54
55 Compliance; Video; Text Messaging; Periodontal Diseases; Dental Plaque; Telemedicine;
56
57 eHealth
58
59
60
61
62
63
64
65

77 BACKGROUND (592 mots)

78 Dental plaque is a bacterial biofilm that is responsible for most periodontal diseases when
79 there is dysbiosis of the oral ecosystem, often due to a lack of oral hygiene [1]. The two main
80 periodontal conditions are gingivitis and periodontitis [2]. In the experimental model of
81 gingivitis, if oral hygiene is reinstated, inflammation is reduced and tissues heal *ad integrum*
82 [3]. If left untreated and compounded by other factors (genetic, environmental, local, etc.),
83 gingivitis evolves to periodontitis in susceptible people [4–6]. In addition to gum inflammation,
84 periodontitis leads to a deeper destructive process targeting the tooth-supporting tissue such as
85 the alveolar bone. Ultimately, this irreversible tissue destruction can lead to the loss of teeth
86 [7]. Other well documented risk factors for periodontitis include smoking and diabetes [5, 8–
87 10].

88 A key aspect of periodontal therapy is the instruction and motivation of patients for a
89 satisfactory level of oral hygiene. Once oral hygiene is established, non-surgical and surgical
90 periodontal care can be initiated. In adults, twice daily toothbrushing and daily interdental care
91 (dental floss or interdental brushes) reduces considerably the amount of dental plaque
92 accumulated on teeth [11–13]. Adequate plaque control reduces the prevalence and the severity
93 of periodontal diseases [14]. It reduces the risk of tooth loss both for healthy patients [15] and
94 for those enrolled in supportive periodontal therapy [16].

95 Several frameworks have been proposed to improve oral hygiene in periodontal patients,
96 among which one can differentiate those that rely mostly on patient education, those that
97 emphasize the use of technology, and those that combine patient education theories and the use
98 of technology. Behavior change techniques can be used by the practitioner to enhance a
99 patient's motivation for durable oral hygiene and healthy habits [17]. One such technique is
100 motivational interviewing (MI), a patient-centered communication technique [18]. MI has been

101 successfully implemented in patient motivation in periodontology [19–22] as well as in
102 smoking cessation advice [23]. Researchers have also proposed several solutions taking
103 advantage of technology. Videos for oral hygiene instruction have not shown any difference
104 when compared to a clinical consultation [24, 25]. But in these studies, the videos were pre-
105 recorded and generic (i.e. non-personalized). Conversely, having a personalized video, filmed
106 by the dentist or the dental hygienist during the consultation, displaying all steps for a correct
107 oral hygiene routine could be worth exploring as patients may relate more easily with images
108 of their own teeth. Frequent recalls have also been shown to increase long-term adherence in
109 patient motivation for oral hygiene [26, 27], and it is of note that for chronic diseases text
110 messages based recalls improved adherence to medication in several trials [28–32].

111 It is possible to combine patient motivation techniques and technological aspects to create
112 innovative eHealth solutions. eHealth is defined as an “emerging field in the intersection of
113 medical informatics, public health and business, referring to health services and information
114 delivered or enhanced through the Internet and related technologies” [33]. The eHealth concept
115 proposed and evaluated in this randomized controlled trial (RCT) features three key aspects: a
116 consultation taking advantage of MI, personalized oral hygiene videos accessible anytime on a
117 smartphone via a cloud portal, and regular and interactive text messages to enhance patient
118 adherence to the oral hygiene routine. To the best of the authors’ knowledge, such a strategy
119 has yet to be evaluated in a RCT.

121 **Objectives and hypotheses**

122 The aim of this randomized trial is to evaluate an eHealth concept for patient motivation
123 for oral hygiene through the combined use of MI, a personalized oral hygiene video, and
124 motivational interactive text messages.

125 The primary objective is the comparison of the level of oral hygiene as assessed by plaque
126 scores (that range from 0 to 100%) of individuals who benefited from the control versus test
127 patient education strategies at 8 weeks. The main secondary objective is the gingival
128 inflammation as assessed by bleeding on probing (BOP) index (the values of which range from
129 0 to 100%) of the control and test groups at 8 weeks. Two secondary objectives will be also
130 considered: the satisfaction after 8 weeks, and patient motivation for change after 4 and 8 weeks
131 for each treatment arm. Interventions are further defined below.

132 The underlying hypothesis is that the eHealth concept for patient motivation for oral
133 hygiene would allow better instruction and motivation for oral hygiene because it gives patients
134 a constant access to a video summarizing their oral hygiene routine, and patients benefit from
135 regular contact via text messages.

136

137 **METHODS**

138 **Trial design**

139 The SPIRIT Statement [34] and SPIRIT-PRO Extension [35] (for patient-reported
140 outcomes) were taken into account for the design of the present clinical trial.

141 This is a multicenter randomized controlled trial with two parallel arms. For the primary
142 objective and secondary objectives, only outcome examiners and data analysts are blinded to
143 the allocated intervention (control or test patient education strategy). Patient randomization is
144 done at the end of the first consultation so that patients and investigators are not aware of the
145 allocation during the patient education and motivation procedure.

146 The randomization is performed (allocation ratio 1:1) for the type of patient education
147 strategy (control vs. test) with a stratification based on center of inclusion, patient gender (male
148 vs. female), and tobacco status (currently using tobacco vs. currently not using tobacco).

149 The flow chart of the study is presented in Figure 1 and the content of each visit is
1
2 150 summarized in Figure 2.

3
4
5 151

6 7 152 **Setting and participants**

8
9 153 This study is carried out in two teaching hospitals, one located in France and the other in
10
11 154 Belgium: the dental teaching hospital of the Lyon university hospitals (Lyon, France) and the
12
13 155 department of periodontology of the Liège university hospital (Liège, Belgium). Patients will
14
15 156 be included from March 2017 until December 2019.

16
17
18
19 157 Eligible patients are informed about the study by dentists and dental students working in
20
21 158 the hospital. Then, a study investigator presents the study to patients and gives them information
22
23 159 letters before inclusion. Ethical approval was obtained in both countries and patient consent is
24
25 160 obtained and recorded in accordance with national regulations.

26
27
28
29 161 To be included in this trial patients must be 18 years old and over, be able to receive dental
30
31 162 care, be capable to read, write, speak and listen to French language. They must have at least 20
32
33 163 teeth including at least 4 permanent molars and 4 permanent premolars forming premolar-molar
34
35 164 interdental sites. They must own an Internet-enabled smartphone or tablet, have an electronic
36
37 165 mail address, agree to be registered in the automatic text messages contact system, agree to
38
39 166 come to the two follow-up appointments, and be covered under the national health insurance
40
41 167 system. Exclusion criteria are : history of periodontal treatment (end of treatment < 1 year),
42
43 168 currently enrolled in a periodontal treatment program, last oral hygiene instruction and
44
45 169 motivation < 1 year ago, last tooth scaling and polishing < 1 month ago, removable partial or
46
47 170 complete dentures, fixed or removable orthodontic appliances, allergy to benzoic acid, under
48
49 171 treatment by an antiplatelet or anticoagulant drug, hemophilia, unable to answer questions,
50
51 172 unable to perform twice daily toothbrushing, unable to perform daily interdental care, using
52
53 173 more than once a week interdental brushes or dental floss, under guardianship, legally deaf or
54
55
56
57
58
59
60
61
62
63
64
65

174 blind, at risk of infectious endocarditis, planning to relocate to another city during the duration
175 of the study. Non-inclusion criteria have been chosen to reduce loss to follow-up or unreliable
176 results.

177 Medications taken by the patient less than 8 days before entering the study are recorded in
178 the electronic case report form (e-CRF). History of or current renal condition, head and neck
179 cancer, diabetes, current and past tobacco usage, as well as other current medical conditions
180 must be reported.

181 No special concomitant care or intervention is prohibited after inclusion in the trial. Patients
182 are specifically instructed to use the material provided for this trial: electric toothbrush (Philips
183 Sonicare, Philips Personal Health France, Suresnes, France); toothpaste (Meridol gum
184 protection, GABA France, Colgate-Palmolive, Bois-Colombes, France); interdental floss
185 (Inava DentoFil Black, Pierre Fabre Oral Care, Castres, France and Meridol expanded dental
186 floss, GABA France, Colgate-Palmolive, Bois-Colombes, France); interdental brushes (Inava
187 Monocompact and Inava Trio Compact, Pierre Fabre Oral Care, Castres, France and Elmex
188 interdental brushes, GABA France, Colgate-Palmolive, Bois-Colombes, France).

189

190 **Sample size**

191 A literature review found that behavioral interventions, similar to the patient education
192 strategy explored in this trial, allow up to 15% reduction of dental plaque [21, 36–39]. However,
193 at the best of the authors' knowledge, there is no publication examining the eHealth concept for
194 patient motivation for oral hygiene proposed herein. A conservative estimate of 10% reduction
195 in PCR index was therefore chosen for the test group compared to the control group.

196 A total of 86 patients enables to show a 10% difference PCR index between the 2 groups
197 with 80% power, using a bilateral test with an alpha risk of 5%. At 8 weeks, 15% of patients
198 are expected to be lost to follow-up (calculated by nQuery Advisor 7.0) [40].

199 To encourage recruitment, the investigators organize regular communications with
1
2 200 colleagues of the teaching hospitals, involve student representatives in the process by having
3
4 201 them promote the study among their classes, and regularly have the study leaflet as the desktop
5
6
7 202 image of computers in the relevant hospital departments. In addition, students who refer a
8
9 203 patient for inclusion in the protocol get extra points for their periodontology practical
10
11
12 204 examination and the patient is referred back to them for the next phases of periodontal therapy.
13
14 205

16 206 **Randomization**

18
19 207 Randomization is performed using a computerized and centralized system via a specific
20
21
22 208 website. A one-stage randomization is conducted stratified on the following potential
23
24 209 confounders: investigation center (Lyon vs. Liège), patient gender (male vs. female), and
25
26 210 patient current tobacco status (currently a tobacco user vs. not currently a tobacco user).
27
28

29 211 Because all patient characteristics must be entered in the e-CRF before interventions are
30
31 212 assigned, sequence concealment is secured.
32
33

34 213 35 214 **Implementation**

36
37
38 215 The stratification algorithm was implemented by statisticians and methodologists
39
40
41 216 independently of investigators. Patients are assigned to intervention arms by the center
42
43 217 coordinator.
44
45

46 218 47 219 **Intervention**

50 220 *Visit 1*

51
52
53 221 At the first visit (T0), eligibility criteria are verified by an investigator. Information about
54
55
56 222 the study is then given orally and by the means of an information letter to the patient. Patient
57
58
59
60
61
62
63
64
65

223 consent is sought and registered according to the national regulations. The inclusion is then
1
2 224 formalized by the creation of a patient file in the e-CRF
3

4 225 A clinical examination is performed to assess periodontal health and level of oral hygiene.
5
6
7 226 Other oral conditions (such as dental caries, TMJ disorders, failing restorations, etc.) will be
8
9 227 further treated by referrals inside the dental teaching hospital according to usual procedures and
10
11 228 will not be considered in this study. Whenever clinically and ethically possible, the treatment
12
13 229 of such conditions will be delayed for a maximum of 8 weeks until the end of the study in order
14
15 230 not to interfere with the evaluation of periodontal parameters (e.g. reducing local plaque
16
17 231 retention factors by repairing or replacing a failing filling). If treatment cannot be delayed, it
18
19 232 will be recorded in the e-CRF.
20
21
22

23
24 233 Then, a 20-minute MI session is conducted. All investigators apply the same structure of
25
26 234 MI to all patients following a dedicated protocol available in the study folder. This MI protocol
27
28 235 is arranged around five themes: reason for seeking consultation, dental and medical history,
29
30 236 everyday consequences of periodontal or dental problems, current routine of oral hygiene,
31
32 237 knowledge of and willingness to get required dental and medical care. Such a framework was
33
34 238 previously validated in a RCT and led to better results than patient instruction alone [36]. The
35
36 239 patient is instructed and motivated for a tailored regimen of oral hygiene following international
37
38 240 recommendations: twice daily electric toothbrushing with a toothpaste containing fluoride
39
40 241 agents, the use of dental floss or interdental brushes, and adjunctive chemical plaque control
41
42 242 agents if needed [11–13, 41–43]. Adjunctive chemical plaque control agents could be used for
43
44 243 instance in case of intense gingivitis to help reduce the total bacterial load. Their use would be
45
46 244 limited to as few patients as possible and for the shortest duration achievable [41], to reduce
47
48 245 interference with results. If such agents must be used, it will be recorded in the e-CRF.
49
50
51
52

53
54 246 The use of an electric toothbrush, interdental brushes, dental floss and toothpaste is
55
56 247 demonstrated to the patients by investigators. The patient then have to demonstrate use
57
58
59
60
61
62
63
64
65

248 themselves and reinstruction is performed if needed. This MI session is provided to all patients,
1
2 249 irrespective of their allocation (test vs. control). All the required materials, including the electric
3
4 250 toothbrush are given to the patient during the MI session in sufficient quantity for the study
5
6
7 251 duration. Patients are specifically instructed to use these tools, and only these, during the study.
8
9 252 An electric toothbrush was chosen as these have shown, with a moderate level of evidence, to
10
11
12 253 lead to better plaque control and better gingivitis reduction than manual toothbrushes [43]. After
13
14 254 the study, patients can keep all materials to continue using them. Replacement heads for the
15
16
17 255 electric toothbrush, and refills for interdental brushes, floss or toothpaste are easily available
18
19 256 for the patients and at a relatively low cost. The end of the study should not prevent them from
20
21
22 257 following the same oral hygiene routine on the long run if they wish to.

24 258 After the MI session, an outcome examiner conducts clinical data collection. The clinical
25
26
27 259 data collection for the primary outcome is conducted using a dental plaque disclosing agent,
28
29 260 with lip and OptraGate cheek retractors (Ivoclar Vivadent France, Saint-Jorioz, France), and
30
31 261 under constant suction.

33
34 262 According to the manufacturer's information, the TriPlaque disclosing agent (GC Europe,
35
36 263 Leuven, Belgium) appears as different colors according to biofilm maturation; new plaque
37
38
39 264 appears as pink-red, mature plaque (> 48 hours) as blue-purple, extra high-risk plaque (pH <
40
41 265 4.5) appears as light blue.

43 266 For data collection, the PCR index [44] is used with 6 sites per teeth (disto-buccal, buccal,
44
45
46 267 mesio-buccal, mesio-lingual, lingual, disto-lingual). All colors are considered as indicating the
47
48
49 268 presence of plaque and therefore the site is coded "1" by the outcome examiner. If no plaque is
50
51 269 present, the site is coded "0". The examination is conducted visually using loupes and a loupe-
52
53 270 mounted light emitting diode; during the examination a periodontal probe is used on the tooth
54
55
56 271 surface with an aim to avoid false-positives and false-negatives.

272 The clinical examination for the secondary outcome is conducted immediately thereafter.

273 A periodontal probe is used to assess the BOP index with six sites per tooth (disto-buccal,
274 buccal, mesio-buccal, mesio-lingual, lingual, and disto-lingual). Criteria for the site to be coded
275 “1” is bleeding within 30 seconds of probing [45], otherwise the site is coded “0”.

276 Then, the investigator records the personalized oral hygiene video. This video is recorded
277 for all patients. The investigator uses a loupe-mounted miniature camera connected to a
278 computer (Futudent Educam, Novocam Medical Innovations Oy, Helsinki, Finland). The video
279 lasts approximately 3 minutes and displays the use of the electric toothbrush the interdental
280 brushes, and the dental floss. It contains audio instructions summarizing what was said to the
281 patient during the consultation, and is to be watched while brushing teeth.

282 After the video recording, the clinical part of the consultation is finished. Patients are then
283 randomized by the center coordinator. Patients allocated to the control group are not given any
284 further detail beyond their allocation. Patients allocated to the test group are registered in the
285 text messages system and their personalized video is uploaded to the cloud portal by the
286 investigator. The investigator instructs them on how the cloud portal and the text messages
287 system work. Both the cloud portal and the text messages system are secured (see Data
288 management, Ethical considerations, and Discussion sections). The cloud portable is accessible
289 via any smartphone, tablet or computer with a web browser, irrespective of their operating
290 system, and there is no need to install an application in an attempt to maximize technical
291 compatibility. As no application is installed, no notifications will be used to remind the patient
292 about watching the video: only text messages will be used.

293 The difference between control and test groups is the availability of the personalized oral
294 hygiene video through the cloud server and the registration of the patient in the interactive text
295 messages system. The two follow-up appointments are scheduled, and the visit is brought to

296 an end. Patients in both groups are not contacted by investigators between visits, except for
297 administrative reasons such as rescheduling an appointment.

298

299 *Text reminders*

300 All text reminders sent to patients have the same structure : salutation, a piece of
301 information regarding oral hygiene and oral health, a question as to whether the patient is
302 compliant to the oral hygiene regiment that was prescribed, an invitation to view the oral
303 hygiene video and a direct link to it, a recall of the date of the next appointment, greetings, and
304 a link to opt-out of the text reminders service (as required by law). The piece of information
305 regarding oral hygiene and oral health varies across messages, in an attempt to keep patients
306 interested in the messages by avoiding repetitions and providing them with new information.
307 This piece of information is chosen in a randomized fashion, and once it has been used, it cannot
308 be used in further messages.

309 Twelve messages are automatically sent during over the course of the study based on the
310 following schedule: the day of visit 1 (V1), the day after V1, two days after V1, a week after
311 V1, 2 weeks after V1, 3 weeks after V1, the day before visit 2 (V2), the day of V2, 1 week after
312 V2, 2 weeks after V2, 3 weeks after V2, 1 day before visit 3.

313 The patient can answer the text messages to tell the investigators if he is or not adherent with
314 the oral hygiene routine that was prescribed to him. To do that, he can reply to the text message
315 he received. The system will register his answer in the database and initiate an automated reply.
316 If the patient is adherent, the reply will include elements of positive reinforcement. If the patient
317 is not adherent, the reply will attempt to play down the situation, reassure the patient and offer
318 to discuss this issue at the next appointment. Enough messages have been written to ensure that
319 they are never repeated. All interactions with the patient through text messages are registered
320 in a database to allow descriptive analysis.

321

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

322 *Visit 2*

323 At the second visit (T0 + 4 weeks), patients are first asked to complete a self-administered
324 electronic questionnaire about their motivation and behavior in terms of oral health [46] that is
325 directly linked to the e-CRF and investigators are blinded to answers. Then, a short (<5 minutes)
326 recall about oral hygiene methods is proposed to the patient and conducted by the investigator
327 if needed.

328 A brief clinical examination is conducted, and the outcome examiner then collects the
329 clinical data. Data collection is conducted following the same protocol as for the first visit.
330 Results are delivered to both the investigator and the patient, and are stored in both the e-CRF
331 and the patient's electronic healthcare records.

332 The investigator then conducts a full-mouth supra- and juxta-gingival tooth scaling and
333 polishing (Acteon ultrasonic tip number 1 and Newtron LED handpiece, Satelec Acteon,
334 Merignac, France). The investigator ensures thorough removal of calculus but avoids
335 instrumenting the gingival pockets. Following completion of the scaling, patients are invited to
336 rinse with a solution containing 0.12% chlorhexidine digluconate (Paroex, Sunstar France,
337 Levallois Perret, France).

338 Additional supplies of interdental brushes and floss are given to the patient if required. The
339 next appointment is confirmed, and the second visit is brought to an end.

340

341 *Visit 3*

342 At the third visit (T0 + 8 weeks), patients are first asked to complete the same questionnaire
343 about their motivation and behaviors for oral health they completed at the second visit. Then, a
344 short (<5 minutes) recall about oral hygiene methods is proposed to the patient and conducted
345 by the investigator if needed.

346 A brief clinical examination is conducted, and the outcome examiner then collects the
1
2 347 clinical data following the same protocol as for the first visit. Results are delivered to both the
3
4 348 investigator and the patient, and are stored in both the e-CRF and the patient's electronic health
5
6
7 349 records.

8
9 350 At the end of the appointment, the patient is asked to complete a satisfaction questionnaire
10
11 351 specially designed for dental care (Dental Visit Satisfaction Scale [47]). Again, data is directly
12
13
14 352 entered by the patient in the e-CRF and investigators are blinded to answers.

15
16
17 353 Participation of the patient in the study is complete at the end of the third visit. Should the
18
19 354 patient require further treatment, they are referred to the relevant departments following
20
21 355 standard hospital protocols. If the patient does not need further treatment, they are informed
22
23
24 356 that they should seek an appointment in 1 year for a check-up, either with the staff of the dental
25
26 357 teaching hospital or with another dental care provider. **The possibility to consult with another**
27
28
29 358 **dental care provider is by law an inalienable right of the patient. The Ethics committee**
30
31 359 **emphasized that it should be reminded to the patient.**

32
33
34 360 Various strategies are implemented to improve adherence to intervention protocols: the
35
36 361 investigators follow dedicated written protocols to structure the MI (T0), to harmonize the oral
37
38
39 362 hygiene videos (T0), and for recalls about oral hygiene (T0 + 4 weeks and T0 + 8 weeks).

40 41 363 42 43 364 **Outcome measures**

44
45
46 365 Data collection is performed at 0, 4, and 8 weeks after patient inclusion by three blinded
47
48 366 independent and calibrated outcome examiners.

49
50
51 367 For the primary objective (oral hygiene) and the main secondary objective (gingival
52
53 368 inflammation) the outcome will be the value of indices collected during the third visit (8 weeks
54
55
56 369 of follow-up). Values range from 0 to 100%.

370 Two additional secondary objectives will be also considered: patient satisfaction after 8
1
2 371 weeks, and patient motivation for change after 4 and 8 weeks for each treatment arm. For the
3
4 372 first secondary objective (patient satisfaction after 8 weeks), the Dental Visit Satisfaction Scale
5
6
7 373 questionnaire [47] comprises 10 multiple choice questions (MCQ) scored on a 5-point Likert
8
9 374 scale, and explores three aspects of patient satisfaction: information-communication,
10
11 375 understanding-acceptance, and technical competence (Supplementary material 1). For the
12
13
14 376 second secondary objective (patient motivation for change after 4 and 8 weeks), a questionnaire
15
16
17 377 featuring 12 questions (MCQ or binary) derived from previous publications is used [46]
18
19 378 (Supplementary material 2). Results from this questionnaire would allow a preliminary
20
21
22 379 understanding of psychological factors predictive of patient motivation and readiness to change
23
24 380 behavior.

25 26 381 27 28 29 382 **Data collection methods**

30
31 383 To promote data quality, investigators and outcome examiners, who will assign scores,
32
33
34 384 are trained in the plaque and gingival inflammation indices by means of group training sessions
35
36 385 on live patients. To evaluate calibration on the primary outcome (plaque control), investigators
37
38
39 386 and examiners are trained on a large number of pictures of teeth; inter-rater agreement is
40
41 387 measured using the Kappa coefficient. Group training sessions and inter-rater agreement
42
43 388 assessment are conducted before the beginning of patient inclusion.

44
45
46 389 For the primary and the main secondary outcome measures, data collection forms are
47
48
49 390 generated through a public online platform [48]. For the patient-reported outcomes (remaining
50
51 391 secondary objectives), patients enter their answers to the questionnaires directly on a dedicated
52
53 392 and password-protected page of the e-CRF. No particular reward to promote participant
54
55
56 393 retention and complete follow-up has been instated.

57
58 394
59
60
61
62
63
64
65

395 **Data management**

1
2 396 Data are entered by investigators and outcome examiners to the e-CRF. Fields cannot be left
3
4 397 blank. Interactive data controls will be applied for value ranges and presence of impossible
5
6
7 398 values as well as between-form coherence. A patient-operated e-CRF allows for the collection
8
9
10 399 of patient-reported outcomes without intervention of study investigators. Data will be kept
11
12 400 anonymous, with high-level security storage, and encryption of all data transfers, in compliance
13
14 401 with French regulatory and ECRIN (European Clinical Research Infrastructure Network)
15
16
17 402 requirements [49].
18

19 403

21 404 **Statistical methods**

22
23
24 405 The statistical unit for analysis will be the patient. All teeth of the patient are considered for
25
26 406 data collection but unerupted, impacted, or fractured teeth are excluded (site-related exclusion
27
28
29 407 criteria). Six sites per tooth are examined.
30

31 408 The demographic and clinical characteristics of patients will be described for both the test
32
33
34 409 and control groups with mean and standard deviation or median and interquartile ranges for
35
36 410 quantitative variables, and number of subjects and percentages for qualitative variables. The
37
38
39 411 analyses will be performed according to the intention-to-treat principle modified to include only
40
41 412 patients with available outcomes.
42

43 413 To respond to the primary objective, the mean plaque score in the test and control groups at
44
45
46 414 8 weeks will be calculated and compared using the Student's *t*-test for unpaired data. The plaque
47
48
49 415 score at third visit will be modelled using a hierarchical model accounting for the correlation
50
51 416 of the measures per patient as well as any possible inter-practitioner heterogeneity. The model
52
53
54 417 will be adjusted on randomization stratification factors (center of inclusion, patient gender, and
55
56 418 tobacco status) as well as the baseline value collected at the first visit. If necessary, other
57
58
59
60
61
62
63
64
65

1
2 419 adjustment factors might also be considered. The main secondary objective (bleeding on
3 420 probing) will be analyzed using the Student's t test (nonparametric test whenever relevant).

4
5 421 In cases of patient non-compliance with follow-up visits, sensitivity analyses will be
6
7 422 performed using the last outcome examiner's assessment (last observation carried forward).
8
9 423 Additional sensitivity analyses will be performed considering all missing data as equal the test
10
11 424 or control group's mean values for the given visit. Candidate factors for subgroup analyses are
12
13 425 patient age, patient gender, diabetic status, tobacco status, at least one general medical
14
15 426 condition.

16 17 18 19 427 **Data monitoring, harms, and auditing**

20
21
22 428 The data will be monitored by an independent clinical research assistant who will
23
24 429 compare the data entered in the e-CRF with those in the patient's electronic health records. In
25
26 430 case of disagreement, the patient's physician will be asked to clarify the data. No interim
27
28 431 analysis is planned. Concerning harms monitoring, specific adverse event forms can be
29
30 432 accessed in the e-CRF. Trial management may be audited by the Agence Nationale pour la
31
32 433 Sécurité du Médicament et des Produits de Santé (ANSM, French medicines agency) at any
33
34 434 time; the audit would be independent of investigators and the sponsor.

35 36 37 38 39 435 40 41 436 **Dissemination of results**

42
43 437 The Consolidated Standards of Reporting Trials (CONSORT [50]) guidelines,
44
45 438 CONSORT Extension for Patient-Reported Outcomes in Randomized Trials (CONSORT PRO
46
47 439 Extension [51]) and the CONSORT Extension for Electronic and Mobile Health Applications
48
49 440 and online Telehealth (CONSORT-EHEALTH [52]) guidelines will be used to report the results
50
51 441 of this study and the results will be published in international peer-reviewed journals. Authors
52
53 442 of the publications will be those involved in the elaboration of the protocol, the implementation
54
55 443 and conduct of the trial, and the drafting of the manuscript and report. The results related to the
56
57
58
59
60
61
62
63
64
65

444 main objective will be authored by the coordinator, the methodologists, the investigators, the
1
2 445 outcome examiners, and others who will have significantly contributed to the planning of the
3
4
5 446 trial, its implementation, or the drafting of the report.

6
7 447 A summary of the study results will be posted on ClinicalTrials.gov to allow general
8
9
10 448 access to the findings. Study participants will be informed about the study results.

11 449 12 13 14 450 **DISCUSSION**

15
16
17 451 The inclusion and non-inclusion criteria for this RCT require patients to have at least 20
18
19 452 teeth and 4 premolar-molar interdental sites. Such criteria can lead to the exclusion of patients
20
21
22 453 affected by severe periodontal disease with several lost teeth. The external validity of the study
23
24 454 for this particular patient population should be interpreted with caution. Yet, two reasons led to
25
26
27 455 this choice. First, the eHealth concept proposed in this trial is applicable in primary prevention
28
29 456 (prior to the onset of any periodontal disease), as well as in secondary prevention (gingivitis)
30
31
32 457 and tertiary prevention (periodontitis). Second, the statistical unit for analysis is the patient. As
33
34 458 such, estimates for patients with few remaining teeth could be less reliable and the planned
35
36 459 statistical analysis does not allow for weighting results from different patients according to
37
38
39 460 number of teeth. Other inclusion and non-inclusion criteria, as well as the overall study
40
41 461 methodology are in line with the recommendations from the Cochrane Oral Health Group [38,
42
43
44 462 53].

45
46 463 Restricting patients' age to a younger group could be discussed as engagement of
47
48
49 464 patients with eHealth is negatively correlated with age although correlation coefficients are
50
51 465 small [54, 55]. But other factors such as educational attainment level [54, 55] and technophilia
52
53 466 [56] also influence patient's attitude towards eHealth. As such, researchers and developers
54
55
56 467 should take into consideration these factors and others in order to overcome barriers to eHealth
57
58 468 for the public they aim at [57, 58]. Application design and user experience are important
59
60
61
62
63
64
65

469 elements in that regard, especially for an elderly population [59]. By keeping the cloud interface
1
2 470 as minimal as possible, we aimed to make it as accessible as possible. Also, this influenced the
3
4 471 choice for a platform that does not require to download and install an application, as it runs
5
6
7 472 entirely within the web browser. Finally, the inclusion of a direct link to the patient's video in
8
9 473 the text reminders further reduces such obstacles as patients only need to click on that link and
10
11
12 474 enter their credentials to consult their video.
13

14 475
15
16
17 476 The choice of a given plaque index has an impact of the statistical analyses – and likely
18
19 477 on the outcomes. Several plaque indices have been developed, with different fields of
20
21
22 478 application [60]. The modified PCR index chosen for this study records presence or absence of
23
24 479 plaque (binary outcome) on 6 sites per tooth. Some indices are more research-oriented such as
25
26
27 480 the Turesky modification of the Quigley-Hein Plaque Index that records plaque as an ordinal
28
29 481 outcome with 6 levels [61, 62] or the Rustogi/Navy Plaque Index that records plaque still as a
30
31
32 482 binary outcome but on 9 sites per tooth [63]. An ordinal outcome and more sites per tooth
33
34 483 dramatically increase the sensitivity of the index, thus allowing the detection of smaller
35
36 484 differences between groups [64, 65]. While the original PCR index proposed by O'Leary et al.
37
38
39 485 used 4 sites per tooth [44], it was decided for this RCT to use 6 sites per tooth to achieve a
40
41 486 balance between clinical practicability and precision for plaque assessment. Also, using a
42
43
44 487 plaque disclosing agent facilitates the detection of plaque [66] but a number of false positives
45
46 488 were detected during the calibration phase of the trial. Taking this finding into consideration,
47
48
49 489 outcome examiners were instructed to use a periodontal probe on the tooth surface when in
50
51 490 doubt, to clear any uncertainty about plaque presence or absence.
52

53 491 In terms of internal validity, the sources of bias are limited by the use of centralized
54
55
56 492 randomization (selection bias), strict prospective data record and monitoring (information bias),
57
58 493 and blinded outcome examiners (performance and detection bias). However, because of the
59
60
61
62
63
64
65

494 nature of the investigation, the patients cannot be blinded. Also, investigators are not blinded
1
2 495 but as the randomization is done at the end of the first visit, it ensures that investigators are not
3
4 496 biased when performing the MI and recording the video.
5
6

7 497
8
9 498 A factorial design would have allowed to explore any interaction between the patient
10
11 499 education strategy (control vs. test eHealth strategy) and the type of toothbrush recommended
12
13 500 during the consultation (electric vs. manual toothbrush). One might consider that correct
14
15 501 demonstration is of major importance for manual toothbrushes and that electric toothbrushes
16
17 502 are less dependent on a patient's brushing technique. Two reasons led to the choice of a two
18
19 503 parallel arm design with electric toothbrushes for all participants. First, the sample size for a
20
21 504 full factorial design (including interactions) would have been of 508 patients without taking
22
23 505 into account patients lost to follow-up. This was beyond the recruitment capacity of the centers
24
25 506 involved so either electric or manual toothbrushes had to be selected for all patients. Second, a
26
27 507 Cochrane review established with a moderate level of evidence that electric toothbrushes are
28
29 508 more effective than manual toothbrushes for plaque removal by 11% and up to 21% when
30
31 509 follow-up is over 3 months [43] so choice was made to favor electric toothbrushes.
32
33
34
35
36
37
38

39 510 To use only one type of toothbrush for all patients also helps to suppress a potential bias
40
41 511 due to the variation in cleaning efficacy between different models of toothbrushes, manual or
42
43 512 electric. However, to generalize the results to all toothbrush designs and validate the added
44
45 513 value of our eHealth solution (video + SMS), further studies would be needed.
46
47

48 514 While electric toothbrushes are more expensive than manual ones, cost to patients was
49
50 515 not an issue for this trial as all oral hygiene materials are provided to them. Lastly, some electric
51
52 516 toothbrushes can be connected to smartphones, which sounds a promising area of research for
53
54 517 enhanced interaction with the patients and adherence monitoring.
55
56
57

58 518
59
60
61
62
63
64
65

519 Patient compliance for oral hygiene is of paramount importance for oral health [15, 67],
520 and patient motivation is the first step of periodontal therapy and instrumental care should not
521 be initiated before plaque control is satisfactory. The focus of the present study is to evaluate
522 the added value of a eHealth platform (video + SMS) for the acquisition of an effective oral
523 hygiene routine. As such, an 8-weeks follow-up is acceptable, and fits with the
524 recommendations from the Cochrane Oral Health Group [38, 53].

525 However, when patients enter supportive periodontal therapy, oral hygiene should be
526 maintained over time in order to entail long-term tooth loss: in a 10-year cohort study, Eickholz
527 et al. found that an increase of 10 points of the PCR index was associated with a risk ratio of
528 1.57 for tooth loss [16]. As such, should the stability over time for oral hygiene adherence be
529 investigated, a much longer follow-up, for instance 1 year, would be required. A 1-year follow-
530 up visit could be organized after further approval by the Ethics committee. Such possibility has
531 been expressly incorporated in the file submitted to the Ethics committee. If a 1-year visit is
532 scheduled, the calibrated researchers from the original 8-weeks study will be responsible for it,
533 in order to standardize protocol.

534
535 The eHealth concept assessed in this RCT aims to take advantage of MI for patient
536 motivation and to create a supportive environment at home through the use of videos and text
537 messages. According to 2016 Eurostat survey, respectively 78% of Belgian and 71% of French
538 residents used their smartphones to access Internet, as often or more often than desktop
539 computers, laptops and tablets [68]. This motivated the choice of a cloud platform compatible
540 with smartphones so that a patient can view his video anytime.

541 As the video is recorded by a healthcare professional, the information delivered through
542 it is of adequate quality. The burden of recording the video is minimized by the small size of
543 the camera, as it can be kept on the dental loupes all the time. Also, the structure of the

544 consultation can be optimized by each practitioner according to their wishes. Recording the
1
2 545 video requires less than 5 additional minutes for the clinician, which is reasonable as the latest
3
4 546 findings suggest that 50% of European periodontal practitioners spend more than 15 minutes for
5
6
7 547 the first phase of patient education before instrumental care [69].
8
9

10 548
11
12 549 Overall, several barriers and facilitators have been identified for the implementation of
13
14 550 eHealth solutions [70]. A recent systematic review indicates that one of the key obstacles is
15
16
17 551 when systems require users to manually enter a lot of data [71]. With the computer framework
18
19 552 used in this RCT, while recording and sharing the video is straightforward, the system
20
21
22 553 supporting text messages is more cumbersome. A gateway to the telephone network had to be
23
24 554 developed separately from the electronic health records system of the teaching hospital and of
25
26 555 the camera software. When registering a new patient in the text messages database, several
27
28
29 556 steps are needed, and the process takes 5-10 minutes. While acceptable in a research
30
31
32 557 environment, these extra steps might affect productivity in a private dental practice. Further
33
34 558 integration of such systems into various practice management software could help streamline
35
36 559 the process.
37

38
39 560 The legislative and regulatory environment should also be taken into consideration. For
40
41 561 the video recording, it might be required in some settings to seek and record patient consent, as
42
43 562 it would be for photographs. Regarding the cloud platform, the solution proposed by the camera
44
45
46 563 manufacturer fully complies with the new European Union General Data Protection Regulation
47
48
49 564 requirements and relies on a certified cloud provider (Microsoft Azure). Similarly, the
50
51 565 telephone network gateway is secured, and all communications are encrypted. If this eHealth
52
53 566 concept is to be disseminated to private practices, practice owners and service providers should
54
55
56 567 pay great attention to the applicable legal and regulatory requirements, in particular regarding
57
58 568 who is responsible for data confidentiality.
59
60
61
62
63
64
65

569

1

2 570

3

4 571

5

6 572

7

8 573

9

10 574

11

12 575

13

14 576

15

16 577

17

18 578

19

20 579

21

22 580

23

24 581

25

26 582

27

28 583

29

30 584

31

32 585

33

34 586

35

36 587

37

38 588

39

40 589

41

42 590

43

44 591

45

46 592

47

48 593

49

50

51

52

53

54

55

56

57

58

59

60

61

62

The present research focuses on the assessment of a novel eHealth concept linking proven behavior change techniques and mobile technology. After motivation for oral hygiene in the dental office, the proposed concept aims to help keep the link with the patient at home and strengthen their long-term commitment for a good oral hygiene routine. The availability of new data should help make a case for an increased use of eHealth solutions by dental practitioners.

Trial status

The trial is currently in the recruitment phase.

Abbreviations

ANSM: Agence Nationale pour la Sécurité du Médicament et des Produits de Santé (French medicines agency, independent state agency)

BOP: bleeding on probing

CNIL: Commission Nationale de l'Informatique et des Libertés (National Commission for Information Technology and Individual Freedom, independent state agency)

CONSORT: Consolidated Standards Of Reporting Trials

CONSORT-EHEALTH: Consolidated Standards of Reporting Trials of Electronic and Mobile Health Applications and onLine TeleHealth

CONSORT-PRO: Consolidated Standards Of Reporting Trials - Patient-Reported Outcomes

e-CRF: electronic case report form

ECRIN: European Clinical Research Infrastructure Network

MCQ: multiple choice question

MI: motivational interviewing

594 RCT: randomized controlled trial

595 SPIRIT: Standard Protocol Items: Recommendations for Interventional Trials

596 SPIRIT-PRO: Standard Protocol Items: Recommendations for Interventional Trials – Patient-

597 Reported Outcomes

598

599 **Ethical considerations**

600 The local ethics committee (Comité de Protection des Personnes Sud-Est IV) in Lyon
601 and the ethics committee of the university hospital of Liège (Comité d’Ethique Hospitalo-
602 Facultaire Universitaire de Liège) have approved the study protocol (registration numbers:
603 16/065 A 16-381 and B707201731667 2017-56, respectively). The protocol is registered with
604 the ANSM (registration number: 2016-A01549-42) and on ClinicalTrials.gov (registration
605 number: NCT03109808). All amendments to the protocol will be justified, submitted to the
606 scientific board, accepted by the ethics committees, and recorded by the ANSM. Changes and
607 amendments will be also recorded on ClinicalTrials.gov. Informed consent will be obtained
608 from participants after the trial is explained to them by an investigator, examiner or coordinator
609 of the corresponding center. Patients are informed that they have the right to withdraw from the
610 study at any time without giving a reason. Regardless of withdrawal, patients will be provided
611 any treatment in their best interest. Withdrawal will be documented. Procedures for data
612 confidentiality were audited by the Commission Nationale de l’Informatique et des Libertés
613 (CNIL, French data protection authority); last and first names of included patients are not
614 recorded in the database.

615 No data monitoring committee is needed for the GoPerio trial as no or very few serious adverse
616 events are expected from this study limited to patient education and routine dental prophylaxis.

617 No interim analysis is planned.

618

619 **Availability of data and material**

1
2 620 Access to the full protocol can be granted to anyone upon request. The datasets generated
3
4 621 and/or analyzed during the current study are available from the corresponding author on
5
6
7 622 reasonable request.
8

9 623

10
11
12 624 **Competing interest**

13
14 625 Authors and investigators did not receive any funding from the industrial partners. However,
15
16 626 all centers involved in the present research protocol received free-of-charge materials (electric
17
18
19 627 toothbrushes, toothpastes, interdental brushes, dental floss, professional prophylaxis materials)
20
21
22 628 and devices (video cameras).

23
24 629 The industrial partners providing materials are:

- 25
26 630 - Futudent / Novocam Medical Innovations Oy, Helsinki, Finland
- 27
28 631 - Philips Personal Health France, Suresnes, France
- 29
30 632 - GC Europe NV, Leuven, Belgium
- 31
32 633 - Ivoclar Vivadent France, Saint-Jorioz, France
- 33
34 634 - Pierre Fabre Oral Care, Castres, France
- 35
36 635 - GABA France, Colgate-Palmolive, Bois-Colombes, France
- 37
38 636 - Komet France SA, Paris, France

39
40
41
42
43
44 637 No other relationships or activities could appear to have influenced the submitted work.

45
46 638 The industrial partners did not have any involvement in the study design or in the analysis,
47
48
49 639 collection and interpretation of the data, or in drafting of the manuscript.
50

51
52 640

53
54 641 **Responsibilities**

55
56 642 The coordination center as a member of sponsor organization is responsible for overall data
57
58
59 643 management, monitoring, and communication between all sites, and general oversight of the
60

644 conduct of the project. The investigator as a member of sponsor organization is responsible for
1
2 645 submitting the report for publication.
3

4 646 The coordination center is accredited by the European Clinical Research Infrastructure Network
5
6
7 647 (ECRIN: <http://www.ecriin.org>).
8

9 648
10

11 **Authors' contributions**

12 649
13
14 650 - BG, KG, VG and FP participated in conception of the study and its design. VG was the main
15
16 651 author of this manuscript. BG, KG and FP contributed equally to this manuscript.
17
18

19 652 - DMB participated in the design of the study and is responsible for the sample size calculation
20
21 653 and biostatistical analysis. She contributed to this manuscript.
22
23

24 654 - FG and PN supervised the design and coordination of the study. They contributed to this
25
26 655 manuscript.
27

28
29 656 - BG supervised the coordination, in accordance with the international guidelines, for the
30
31 657 centers of Lyon and Liège. BG and KG coordinated the Lyon center. FL coordinated the Liège
32
33 658 center.
34
35

36 659 - FP and VG were the operators.
37

38
39 660 - BT, JS, KG and WA were the outcome examiners.
40

41 661 - All authors read and approved the final manuscript.
42

43 662
44

45 **Authors' information**

46 663 Valentin Garyga. *Université de Lyon, Université Lyon 1, Faculté d'odontologie, Lyon, France*
47

48 664 ; *Hospices Civils de Lyon, Service de Consultations et Traitements Dentaires, Lyon, France*
49
50

51 665 . valentin.garyga@chu-lyon.fr
52
53

54 666
55 667 Florian Pochelu. *Hospices Civils de Lyon, Service de Consultations et Traitements Dentaires,*
56
57

58 668 *Lyon, France.* pochelu.florian@gmail.com
59
60
61
62
63
64
65

669 Béatrice Thivichon-Prince. *Université de Lyon, Université Lyon 1, Faculté d'odontologie,*
1
2 670 *Lyon, France ; Hospices Civils de Lyon, Service de Consultations et Traitements Dentaires,*
3
4 671 *Lyon, France ; Université de Lyon, IGFL UMR 5242, Lyon, France. [beatrice.thivichon-
6 prince@univ-lyon1.fr](mailto:beatrice.thivichon-
5 prince@univ-lyon1.fr)*
7
8
9 673 Walid Aouini. *Université de Monastir, Monastir, Tunisia ; CHU de Liège, Liège, Belgium.*
10
11 674 aouiniwalid131177@gmail.com
12
13
14 675 Julie Santamaria. *Hospices Civils de Lyon, Service de Consultations et de Traitements*
15
16 676 *Dentaires, Lyon, France. julie.santamaria@chu-lyon.fr*
17
18
19 677 France Lambert. *Université de Liège, Liège, Belgium ; CHU de Liège, Liège, Belgium ; Dental*
20
21 678 *Biomaterials Research Unit, Liège, Belgium. france.lambert@chu.ulg.ac.be*
22
23
24 679 Delphine Maucort-Boulch. *Université de Lyon, Université Lyon 1, Lyon, France ; Hospices*
25
26 680 *Civils de Lyon, Service de Biostatistique-Bioinformatique, Lyon, France ; Université de Lyon,*
27
28 681 *CNRS UMR 5558, Laboratoire de Biométrie et Biologie Évolutive, Département Biostatistiques*
29
30 682 *et Modélisation pour la Santé et l'environnement, Villeurbanne, France [delphine.maucort-
32 boulch@chu-lyon.fr](mailto:delphine.maucort-
31 boulch@chu-lyon.fr)*
33
34
35
36 684 Francois Gueyffier. *Université de Lyon, Université Lyon 1, Lyon, France ; Hospices Civils de*
37
38 685 *Lyon, Hôpital Cardiologique, Bron, France ; Université de Lyon, CNRS UMR 5558,*
39
40 686 *Laboratoire de Biométrie et Biologie Évolutive, Département Biostatistiques et Modélisation*
41
42 687 *pour la Santé et l'environnement, Villeurbanne, France. francois.gueyffier@univ-lyon1.fr*
43
44
45
46 688 Kerstin Gritsch. *Université de Lyon, Université Lyon 1, Faculté d'odontologie, Lyon, France ;*
47
48 689 *Hospices Civils de Lyon, Service de Consultations et de Traitements Dentaires, Lyon, France ;*
49
50 690 *Université de Lyon, LMI UMR CNRS 5615, Lyon, France. kerstin.gritsch@univ-lyon1.fr*
51
52
53 691 Brigitte Grosgeat. *Université de Lyon, Université Lyon 1, Faculté d'odontologie, Lyon,*
54
55 692 *France ; Hospices Civils de Lyon, Service de Consultations et de Traitements Dentaires, Lyon,*
56
57
58
59
60
61
62
63
64
65

693 *France, Lyon, France ; Université de Lyon, LMI UMR CNRS 5615, Lyon, France.*

694 brigitte.grosgogeat@univ-lyon1.fr

695

696 All authors are members of the Scientific Board of the present trial.

697 The members of the coordination center are: Halla Djadoudi (coordinator), H el ene Lozano

698 (monitor), Patrick Grivot (data manager), Delphine Maucort-Boulch (Biostatistics), Patrice

699 Nony (methodologist) and Fran ois Gueyffier (methodologist).

700

701 **Acknowledgements**

702 This project was supported by a joint scholarship from the Association for Dental Education in

703 Europe and Futudent / Novocam Medical Innovations Oy in the form of a lease of the required

704 cameras and relevant training and technical support. These sources had no involvement in the

705 study design, or in the analysis, collection and interpretation of the data, or in drafting of the

706 manuscript.

707

708 **References**

709 1. L oe H. Oral hygiene in the prevention of caries and periodontal disease. *Int Dent J*.

710 2000;50:129–39. doi:10.1111/j.1875-595X.2000.tb00553.x.

711 2. Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. *Lancet*.

712 2005;366:1809–20. doi:10.1016/S0140-6736(05)67728-8.

713 3. L oe H, Theilade E, Jensen SB. Experimental Gingivitis in Man. *J Periodontol*.

714 1965;36:177–87. doi:10.1902/jop.1965.36.3.177.

715 4. Meyle J, Chapple I. Molecular aspects of the pathogenesis of periodontitis. *Periodontol*

716 2000. 2015;69:7–17.

717 5. Bouchard P, Carra MC, Boillot A, Mora F, Rang e H. Risk factors in periodontology: a

- 718 conceptual framework. *J Clin Periodontol.* 2017;44:125–31. doi:10.1111/jcpe.12650.
- 1
2 719 6. Lang NP, Schätzle MA, Loe H. Gingivitis as a risk factor in periodontal disease. *J Clin*
3
4
5 720 *Periodontol.* 2009;36 SUPPL. 10:3–8. doi:10.1111/j.1600-051X.2009.01415.x.
- 6
7 721 7. Kocher T, Konig J, Dzierzon U, Sawaf H, Plagmann H-C. Disease progression in
8
9
10 722 periodontally treated and untreated patients - a retrospective study. *J Clin Periodontol.*
11
12 723 2000;27:866–72. doi:10.1034/j.1600-051x.2000.027011866.x.
- 13
14 724 8. Ramseier CA. Potential impact of subject-based risk factor control on periodontitis. *J Clin*
15
16
17 725 *Periodontol.* 2005;32:283–90. doi:10.1111/j.1600-051X.2005.00798.x.
- 18
19 726 9. Chapple ILC, Genco R. Diabetes and periodontal diseases: consensus report of the Joint
20
21
22 727 EFP/AAP Workshop on Periodontitis and Systemic Diseases. *J Clin Periodontol.* 2013;40
23
24 728 SUPPL. 14:S106–12. doi:10.1111/jcpe.12077.
- 25
26
27 729 10. Sanz M, Ceriello A, Buysschaert M, Chapple I, Demmer RT, Graziani F, et al. Scientific
28
29 730 evidence on the links between periodontal diseases and diabetes: Consensus report and
30
31
32 731 guidelines of the joint workshop on periodontal diseases and diabetes by the International
33
34 732 Diabetes Federation and the European Federation of Periodontology. *J Clin Periodontol.*
35
36 733 2017; July 2017:138–49. doi:10.1111/jcpe.12808.
- 37
38
39 734 11. Jordan RA, Hong HM, Lucaciu A, Zimmer S. Efficacy of straight versus angled
40
41 735 interdental brushes on interproximal tooth cleaning: A randomized controlled trial. *Int J Dent*
42
43
44 736 *Hyg.* 2014;12:152–7.
- 45
46 737 12. Chongcharoen N, Lulic M, Lang NP. Effectiveness of different interdental brushes on
47
48
49 738 cleaning the interproximal surfaces of teeth and implants: A randomized controlled, double-
50
51 739 blind cross-over study. *Clin Oral Implants Res.* 2012;23:635–40.
- 52
53 740 13. Slot DE, Dörfer CE, Van der Weijden GA. The efficacy of interdental brushes on plaque
54
55
56 741 and parameters of periodontal inflammation: a systematic review. *International journal of*
57
58 742 *dental hygiene.* 2008;6:253–64.
- 59
60
61
62
63
64
65

- 743 14. van der Weijden GA, Hioe KPK. A systematic review of the effectiveness of self-
1
2 744 performed mechanical plaque removal in adults with gingivitis using a manual toothbrush. J
3
4 745 Clin Periodontol. 2005;32:214–28. doi:10.1111/j.1600-051X.2005.00795.x.
5
6
7 746 15. Kressin NR, Boehmer U, Nunn ME, Spiro A. Increased Preventive Practices Lead to
8
9 747 Greater Tooth Retention. J Dent Res. 2003;82:223–7. doi:10.1177/154405910308200314.
10
11
12 748 16. Eickholz P, Kaltschmitt J, Berbig J, Reitmeir P, Pretzl B. Tooth loss after active
13
14 749 periodontal therapy. 1: patient-related factors for risk, prognosis, and quality of outcome. J
15
16 750 Clin Periodontol. 2008;35:165–74. doi:10.1111/j.1600-051X.2007.01184.x.
17
18
19 751 17. Newton JT, Asimakopoulou K. Managing oral hygiene as a risk factor for periodontal
20
21 752 disease: a systematic review of psychological approaches to behaviour change for improved
22
23 753 plaque control in periodontal management. J Clin Periodontol. 2015;42:S36–46.
24
25
26 754 doi:10.1111/jcpe.12356.
27
28
29 755 18. Miller WR, Rollnick S. Motivational Interviewing : Helping People Change. 3rd Edit. The
30
31 756 Guilford Press; 2012.
32
33
34 757 19. Kopp SL, Ramseier CA, Ratka-Krüger P, Woelber JP. Motivational Interviewing As an
35
36 758 Adjunct to Periodontal Therapy—A Systematic Review. Front Psychol. 2017;8 FEB:279.
37
38 759 doi:10.3389/fpsyg.2017.00279.
39
40
41 760 20. Stenman J, Lundgren J, Wennström JL, Ericsson JS, Abrahamsson KH. A single session
42
43 761 of motivational interviewing as an additive means to improve adherence in periodontal
44
45 762 infection control: a randomized controlled trial. J Clin Periodontol. 2012;39:947–54.
46
47 763 doi:10.1111/j.1600-051X.2012.01926.x.
48
49
50
51 764 21. Gao X, Lo ECM, Kot SCC, Chan KCW. Motivational interviewing in improving oral
52
53 765 health: a systematic review of randomized controlled trials. J Periodontol. 2014;85:426–37.
54
55 766 doi:10.1902/jop.2013.130205.
56
57
58 767 22. Cascaes AM, Bielemann RM, Clark VL, Barros AJD. Effectiveness of motivational
59
60
61
62
63
64
65

768 interviewing at improving oral health: a systematic review. *Rev Saude Publica*. 2014;48:142–
1
2 769 53. doi:10.1590/S0034-8910.2014048004616.
3
4
5 770 23. Ramseier CA, Suvan JE. Behaviour change counselling for tobacco use cessation and
6
7 771 promotion of healthy lifestyles: a systematic review. *J Clin Periodontol*. 2015;42:S47–58.
8
9 772 doi:10.1111/jcpe.12351.
10
11
12 773 24. Lim LP, Davies WI, Yuen KW, Ma MH. Comparison of modes of oral hygiene
13
14 774 instruction in improving gingival health. *J Clin Periodontol*. 1996;23:693–7.
15
16
17 775 25. Glavind L, Zeuner E. Evaluation of a television-tape demonstration for the reinforcement
18
19 776 of oral hygiene instruction. *J Clin Periodontol*. 1986;13:201–4.
20
21
22 777 26. Farooqi OA, Wehler CJ, Gibson G, Jurasic MM, Jones JA. Appropriate Recall Interval for
23
24 778 Periodontal Maintenance: A Systematic Review. *J Evid Based Dent Pract*. 2015;15:171–81.
25
26 779 doi:10.1016/j.jebdp.2015.10.001.
27
28
29 780 27. Beirne P, Clarkson JE, Worthington H V. Recall intervals for oral health in primary care
30
31 781 patients. *Cochrane Database Syst Rev*. 2007;:CD004346.
32
33
34 782 28. Lima ICV de, Galvão MTG, Alexandre H de O, Lima FET, Araújo TL de. Information
35
36 783 and communication technologies for adherence to antiretroviral treatment in adults with
37
38 784 HIV/AIDS. *Int J Med Inform*. 2016;92:54–61. doi:10.1016/j.ijmedinf.2016.04.013.
39
40
41 785 29. Pop-Eleches C, Thirumurthy H, Habyarimana JP, Zivin JG, Goldstein MP, de Walque D,
42
43 786 et al. Mobile phone technologies improve adherence to antiretroviral treatment in a resource-
44
45 787 limited setting: a randomized controlled trial of text message reminders. *AIDS*. 2011;25:825–
46
47
48 788 34. doi:10.1097/QAD.0b013e32834380c1.
49
50
51 789 30. Lester RT, Ritvo P, Mills EJ, Kariri A, Karanja S, Chung MH, et al. Effects of a mobile
52
53 790 phone short message service on antiretroviral treatment adherence in Kenya (WelTel
54
55 791 Kenya1): A randomised trial. *Lancet*. 2010;376:1838–45. doi:10.1016/S0140-6736(10)61997-
56
57
58 792 6.
59
60
61
62
63
64
65

- 793 31. Montes JM, Medina E, Gomez-Beneyto M, Maurino J. A short message service (SMS)-
1
2 794 based strategy for enhancing adherence to antipsychotic medication in schizophrenia.
3
4 795 Psychiatry Res. 2012;200:89–95. doi:10.1016/j.psychres.2012.07.034.
5
6
7 796 32. Thakkar J, Kurup R, Laba T-L, Santo K, Thiagalingam A, Rodgers A, et al. Mobile
8
9 797 Telephone Text Messaging for Medication Adherence in Chronic Disease. JAMA Intern Med.
10
11
12 798 2016;176:340. doi:10.1001/jamainternmed.2015.7667.
13
14 799 33. Eysenbach G. What is e-health? J Med Internet Res. 2001;3:e20.
15
16
17 800 doi:10.2196/jmir.3.2.e20.
18
19 801 34. Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al.
20
21 802 SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. Ann Intern
22
23
24 803 Med. 2013;158:200. doi:10.7326/0003-4819-158-3-201302050-00583.
25
26 804 35. Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan A-W, King MT, et al. Guidelines
27
28
29 805 for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols. JAMA. 2018;319:483.
30
31 806 doi:10.1001/jama.2017.21903.
32
33
34 807 36. Godard A, Dufour T, Jeanne S. Application of self-regulation theory and motivational
35
36 808 interview for improving oral hygiene: A randomized controlled trial. J Clin Periodontol.
37
38
39 809 2011;38:1099–105.
40
41 810 37. Jönsson B, Öhrn K, Oscarson N, Lindberg P. The effectiveness of an individually tailored
42
43 811 oral health educational programme on oral hygiene behaviour in patients with periodontal
44
45
46 812 disease: a blinded randomized-controlled clinical trial (one-year follow-up). J Clin
47
48 813 Periodontol. 2009;36:1025–34. doi:10.1111/j.1600-051X.2009.01453.x.
49
50
51 814 38. Renz a, Ide M, Newton T, Robinson PG, Smith D. Psychological interventions to
52
53 815 improve adherence to oral hygiene instructions in adults with periodontal diseases. Cochrane
54
55
56 816 Database Syst Rev. 2007;:CD005097.
57
58 817 39. Stewart JE, Jacobs-Schoen M, Padilla MR, Maeder LA, Wolfe GR, Hartz GW. The effect
59
60
61
62
63
64
65

1 818 of a cognitive behavioral intervention on oral hygiene. *J Clin Periodontol.* 1991;18:219–22.
2 819 doi:10.1111/j.1600-051X.1991.tb00418.x.
3
4 820 40. Lachin JM. Introduction to Sample Size Determination and Power Analysis for Clinical
5
6
7 821 Trials. *Control Clin Trials.* 1981;2:93–113.
8
9 822 41. Tonetti MS, Eickholz P, Loos BG, Papapanou P, van der Velden U, Armitage G, et al.
10
11 823 Principles in prevention of periodontal diseases. *J Clin Periodontol.* 2015;42:S5–11.
12
13 824 doi:10.1111/jcpe.12368.
14
15
16 825 42. Jepsen S, Blanco J, Buchalla W, Carvalho JC, Dietrich T, Dörfer C, et al. Prevention and
17
18
19 826 control of dental caries and periodontal diseases at individual and population level: consensus
20
21 827 report of group 3 of joint EFP/ORCA workshop on the boundaries between caries and
22
23
24 828 periodontal diseases. *J Clin Periodontol.* 2017;44:S85–93. doi:10.1111/jcpe.12687.
25
26
27 829 43. Yaacob M, Worthington H, Deacon S, Deery C, Walmsley A, Robinson P, et al. Powered
28
29 830 versus manual toothbrushing for oral health (Review). *Cochrane Database Syst Rev.*
30
31 831 2014;:CD002281.
32
33
34 832 44. O’Leary TJ, Drake RB, Naylor JE. The plaque control record. *J Periodontol.* 1972;43:38.
35
36 833 45. Ainamo J, Bay I. Problems and proposals for recording gingivitis and plaque. *Int Dent J.*
37
38 834 1975;25:229–35. <http://www.ncbi.nlm.nih.gov/pubmed/1058834>.
39
40
41 835 46. Saito A, Kikuchi M, Ueshima F, Matsumoto S, Hayakawa H, Masuda H, et al.
42
43 836 Assessment of oral self-care in patients with periodontitis: a pilot study in a dental school
44
45
46 837 clinic in Japan. *BMC Oral Health.* 2009;9:27. doi:10.1186/1472-6831-9-27.
47
48 838 47. Corah NL, O’Shea RM, Pace LF, Seyrek SK. Development of a patient measure of
49
50
51 839 satisfaction with the dentist: the Dental Visit Satisfaction Scale. *J Behav Med.* 1984;7:367–73.
52
53 840 48. Department of Periodontology at University of Bern (Switzerland). Periodontal Chart
54
55 841 Online. <http://www.periodontalchart-online.com/>.
56
57
58 842 49. Canham S, Clivio L, Cornu C, Crocombe W, De Bremaeker N, Domingues C, et al.
59
60
61
62
63
64
65

843 Requirements for Certification of ECRIN Data Centres, with Explanation and Elaboration of
1
2 844 Standards, Version 3.0. 2015. doi:10.5281/ZENODO.32690.
3
4
5 845 50. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for
6
7 846 reporting parallel group randomised trials. *BMJ*. 2010;340 mar23 1:c332–c332.
8
9 847 doi:10.1136/bmj.c332.
10
11
12 848 51. Calvert M, Blazeby J, Altman DG, Revicki D a, Moher D, Brundage MD, et al. Reporting
13
14 849 of Patient-Reported Outcomes in Randomized Trials. *JAMA*. 2013;309:814.
15
16 850 doi:10.1001/jama.2013.879.
17
18
19 851 52. Eysenbach G. CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports
20
21 852 of Web-based and Mobile Health Interventions. *J Med Internet Res*. 2011;13:e126.
22
23 853 doi:10.2196/jmir.1923.
24
25
26 854 53. Soldani F a., Young L, Jones K, Walsh T, Clarkson JE. One-to-one oral hygiene advice
27
28 855 provided in a dental setting for oral health. *Cochrane Database Syst Rev*. 2008.
29
30
31 856 54. Rosalía Vicente M, Madden G. Assessing eHealth skills across Europeans. *Heal Policy*
32
33 857 *Technol*. 2017;6:161–8. doi:10.1016/j.hlpt.2017.04.001.
34
35
36 858 55. Del Giudice P, Bravo G, Poletto M, De Odorico A, Conte A, Brunelli L, et al. Correlation
37
38 859 Between eHealth Literacy and Health Literacy Using the eHealth Literacy Scale and Real-
39
40 860 Life Experiences in the Health Sector as a Proxy Measure of Functional Health Literacy:
41
42 861 Cross-Sectional Web-Based Survey. *J Med Internet Res*. 2018;20:e281.
43
44 862 doi:10.2196/jmir.9401.
45
46
47 863 56. Anderberg P, Eivazzadeh S, Berglund JS. A Novel Instrument for Measuring Older
48
49 864 People’s Attitudes Toward Technology (TechPH): Development and Validation. *J Med*
50
51 865 *Internet Res*. 2019;21:e13951. doi:10.2196/13951.
52
53
54 866 57. Kim H, Xie B. Health literacy in the eHealth era: A systematic review of the literature.
55
56 867 *Patient Educ Couns*. 2017;100:1073–82. doi:10.1016/j.pec.2017.01.015.
57
58
59
60
61
62
63
64
65

- 868 58. Scott Kruse C, Karem P, Shifflett K, Vegi L, Ravi K, Brooks M. Evaluating barriers to
1
2 869 adopting telemedicine worldwide: A systematic review. *J Telemed Telecare*. 2018;24:4–12.
3
4 870 doi:10.1177/1357633X16674087.
5
6
7 871 59. Wildenbos GA, Jaspers MWM, Schijven MP, Dusseljee- Peute LW. Mobile health for
8
9 872 older adult patients: Using an aging barriers framework to classify usability problems. *Int J*
10
11
12 873 *Med Inform*. 2019;124:68–77. doi:10.1016/j.ijmedinf.2019.01.006.
13
14 874 60. Pretty IA, Edgar WM, Smith PW, Higham SM. Quantification of dental plaque in the
15
16 875 research environment. *J Dent*. 2005;33 3 SPEC. ISS.:193–207.
17
18
19 876 61. Turesky S, Gilmore ND, Glickman I. Reduced Plaque Formation by the Chloromethyl
20
21 877 Analogue of Victamine C. *J Periodontol*. 1970;41:41–3. doi:10.1902/jop.1970.41.41.41.
22
23
24 878 62. Quigley GA, Hein JW. Comparative cleansing efficiency of manual and power brushing. *J*
25
26 879 *Am Dent Assoc*. 1962;65:26–9. <http://www.ncbi.nlm.nih.gov/pubmed/14489483>.
27
28
29 880 63. Rustogi KN, Curtis JP, Volpe AR, Kemp JH, McCool JJ, Korn LR. Refinement of the
30
31 881 Modified Navy Plaque Index to increase plaque scoring efficiency in gumline and
32
33
34 882 interproximal tooth areas. *J Clin Dent*. 1992;3 Suppl C:C9-12.
35
36 883 <http://www.ncbi.nlm.nih.gov/pubmed/1306676>.
37
38
39 884 64. Deinzer R, Jahns S, Harnacke D. Establishment of a New Marginal Plaque Index With
40
41 885 High Sensitivity for Changes in Oral Hygiene. *J Periodontol*. 2014;85:1730–8.
42
43 886 doi:10.1902/jop.2014.140285.
44
45
46 887 65. Colliot C, Boillot A, Bouchard P. Indices parodontaux. In: Bouchard P, editor.
47
48 888 *Parodontologie et Dentisterie Implantaire - Volume 1 : Médecine Parodontale*. 1st edition.
49
50
51 889 Paris; 2015. p. 150–4.
52
53 890 66. Furuichi Y, Lindhe J, Ramberg P, Volpe AR. Patterns of de novo plaque formation in the
54
55 891 human dentition. *J Clin Periodontol*. 1992;19:423–33. doi:10.1111/j.1600-
56
57 892 051X.1992.tb00673.x.
58
59
60
61
62
63
64
65

- 893 67. Kumar S, Tadakamadla J, Johnson NW. Effect of Toothbrushing Frequency on Incidence
1
2 894 and Increment of Dental Caries. J Dent Res. 2016;95:1–7. doi:10.1177/0022034516655315.
3
4 895 68. Eurostat. Internet use by individuals - Almost 8 out of 10 internet users in the EU surfed
5
6
7 896 via a mobile or smart phone in 2016. 2016.
8
9 897 [https://ec.europa.eu/eurostat/documents/2995521/7771139/9-20122016-BP-EN.pdf/f023d81a-
13
14 899 69. Garyga V, Seidel L, Gagnot G, Renèrs M, Lambert F. O082: Oral hygiene instructions
15
16
17 900 and methods: a European survey among dental professionals - the eSIP study. J Clin
18
19 901 Periodontol. 2018;45:35–35. doi:10.1111/jcpe.81_12913.
20
21 902 70. World Health Organization - Regional Office for Europe. From Innovation to
22
23
24 903 implementation : eHealth in the WHO European Region. Copenhagen; 2016.
25
26 904 \[http://www.euro.who.int/fr/publications/abstracts/from-innovation-to-implementation-
30
31 906 71. Macdonald EM, Perrin BM, Kingsley MI. Enablers and barriers to using two-way
32
33
34 907 information technology in the management of adults with diabetes: A descriptive systematic
35
36 908 review. J Telemed Telecare. 2017;0:1357633X1769999. doi:10.1177/1357633X17699990.
37
38
39 909\]\(http://www.euro.who.int/fr/publications/abstracts/from-innovation-to-implementation-
27
28
29 905 ehealth-in-the-who-european-region-2016\)](https://ec.europa.eu/eurostat/documents/2995521/7771139/9-20122016-BP-EN.pdf/f023d81a-
10
11
12 898 dce2-4959-93e3-8cc7082b6edd)

41 910 **Figures**

42
43 911 Figure 1, title:

44
45
46 912 Flow chart
47
48
49 913

50
51 914 Figure 1, legend:

52
53 915 ¹ PCR = plaque control record
54
55

56 916 ² BOP = bleeding on probing
57

58 917 ³ DVSS = dental visit satisfaction scale
59
60
61
62
63
64
65

918

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

919 Figure 2, title:

920 Content of the study visits

921

922 Figure 2, legend:

923 ¹ PCR = plaque control record

924 ² BOP = bleeding on probing

Figure 1 Flowchart




Figure 2: Schedule of enrolment, interventions, and assessments

TIMEPOINT	STUDY PERIOD				
	Enrolment	Allocation	Post-allocation		Close-out
	<i>Before t₀</i>	<i>t₀</i>	<i>First visit (t₀)</i>	<i>Second visit (t₀ + 4 weeks)</i>	<i>Third visit (t₀ + 8 weeks)</i>
ENROLMENT:					
<i>Eligibility screen</i>	X				
<i>Informed consent</i>	X				
<i>Registration in eCRF</i>	X				
<i>Medical and dental history, ongoing medications</i>	X				
<i>Allocation</i>		X			
INTERVENTIONS:					
<i>Motivational interviewing</i>			X		
<i>Oral Hygiene video recording</i>			X		
<i><u>Test</u> - Video on cloud & text messages</i>			◆—————◆		
<i><u>Control</u> – Video not available & no text messages</i>			◆—————◆		
<i>Tooth scaling and polishing</i>				X	
<i>Brief motivational interviewing</i>				X	X
<i>Assessment of the need for additional therapy</i>					X
ASSESSMENTS:					
<i>Stratification variables (Center, Gender, Smoking status)</i>		X			
<i>Dental plaque (Plaque Control Record)</i>			X	X	X
<i>Gingival inflammation (Bleeding On Probing)</i>			X	X	X
<i>Patient motivation (ad-hoc questionnaire)</i>				X	X
<i>Patient satisfaction (Dental Visit Satisfaction Scale)</i>					X
<i>Clinical time spent with patient (minutes)</i>			X	X	X

Visit 1 (T0)

Patient motivation and video recording
(1 hr)

Investigator

Motivational Interviewing
(20 minutes)

Five questions help structure the MI

Outcome examiner

Clinical data collection
(20 min)

PCR¹ index with plaque disclosing gel
BOP² index

Investigator

Intra-oral explanation for tooth brushing & interdental brushing
(10 min)

Investigator

Recording of the watch-and-follow oral hygiene video
(10 min)

With loupe-mounted camera
Recorded for all patients but only used for patients in the test group

Coordinator

Randomization

Ratio 1:1
Stratification on center, gender and tobacco use

Test group

Text-message recalls
Home-available custom oral hygiene video (via cloud)

Control group

No text-messages
No home-available video

End of appointment

Visit 2 (T0 + 4 weeks)

Recall and scale and polish
(50 min)

Patient

Behavior change and motivation questionnaire
(5 min)

Outcome examiner

Clinical data collection
(20 min)

PCR¹ index with plaque disclosing gel
BOP² index

Investigator

Mini motivational Interviewing
(5 min - optional)

If need be, the patient in re-instructed about plaque control methods

Scale and polish
(20 min)

End of appointment

Visit 3 (T0 + 8 weeks)

Last recall and end of study
(40 min)

Patient

Patient-declared behavior change questionnaire
(5 min)

Outcome examiner

Clinical data collection
(20 min)

PCR¹ index with plaque disclosing gel
BOP² index

Investigator

Mini motivational Interviewing
(5 min - optional)

If need be, the patient in re-instructed about plaque control methods

Patient

Patient satisfaction questionnaire
(5 min)

Dental Visit Satisfaction Scale

Investigator

Assessment for the need of additional therapy
(5 min)

End of appointment - End of patient's participation to the study



Click here to access/download

Supplementary Material

Supplementary material 1 - Satisfaction questionnaire
DVSS.pdf





[Click here to access/download](#)

Supplementary Material

[Supplementary material 2 - behavioral questionnaire.pdf](#)





SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Yes	No	NA	Page of manuscript
Administrative information						
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	X			1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	X			3
	2b	All items from the World Health Organization Trial Registration Data Set			X	
Protocol version	3	Date and version identifier	X			
Funding	4	Sources and types of financial, material, and other support	X			22
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	X			1, 23-25

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

	5b	Name and contact information for the trial sponsor	X			3
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	X			23
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	X			23,24
Introduction						
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	X			4,5
	6b	Explanation for choice of comparators	X			4,5
Objectives	7	Specific objectives or hypotheses	X			5,6

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	X			6
--------------	---	---	---	--	--	---

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Methods: Participants, interventions, and outcomes						
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	X			6,7
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	X			7
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	X			9-13
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)			X	
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	X			13
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial			X	

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	X			13,14
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	X			9-13 and Figure 1
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	X			8
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	X			8

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Methods: Assignment of interventions (for controlled trials)							
Allocation:							
Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	X				9
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	X				9
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	X				9
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	X				6,12,13

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial			X	
Methods: Data collection, management, and analysis						
Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	X			10-12
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	X			14
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	X			14

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	X			15
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	X			15
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	X			15
Methods: Monitoring						
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	X			16,17
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial			X None are planned	(16

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	X			16
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	X			16

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Ethics and dissemination						
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	X			16
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	X			16
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	X			21,22
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable			X	
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	X			16
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	X			22,23

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	X			17
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation			X	
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	X			17
	31b	Authorship eligibility guidelines and any intended use of professional writers	X			17
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	X			17
Appendices						
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	X			7 (Available upon request from authors)

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable			X	
----------------------	----	--	--	--	---	--

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.